Irrespective of these remaining questions, the picture emerges that targeting individual sphingosine kinases or selected S1P receptors such as S1PR4 or S1PR5 may have the highest potential in unleashing the power of the anti-tumor immune response. The gene discussed is S1PR5; the disease is neoplasm.